4D Molecular Therapeutics, Inc.
FDMT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $90 | $15 | $14 | $1 |
| % Growth | 500% | 7.1% | 1,300% | – |
| Cost of Goods Sold | $47,238 | $47,951 | $0 | $1,784 |
| Gross Profit | -$47,148 | -$47,936 | $14 | -$1,783 |
| % Margin | -52,386.7% | -319,573.3% | 100% | -178,300% |
| R&D Expenses | $49,438 | $47,951 | $40,699 | $43,085 |
| G&A Expenses | $11,837 | $11,520 | $12,936 | $13,033 |
| SG&A Expenses | $11,837 | $11,520 | $12,936 | $14,627 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $1,594 |
| Other Operating Expenses | -$47,238 | -$47,951 | $0 | -$3,378 |
| Operating Expenses | $14,037 | $11,520 | $53,635 | $54,334 |
| Operating Income | -$61,185 | -$59,456 | -$53,621 | -$56,117 |
| % Margin | -67,983.3% | -396,373.3% | -383,007.1% | -5,611,700% |
| Other Income/Exp. Net | $4,309 | $4,798 | $5,649 | $6,446 |
| Pre-Tax Income | -$56,876 | -$54,658 | -$47,972 | -$49,671 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$56,876 | -$54,658 | -$47,972 | -$49,671 |
| % Margin | -63,195.6% | -364,386.7% | -342,657.1% | -4,967,100% |
| EPS | -1.01 | -0.98 | -0.86 | -0.9 |
| % Growth | -3.1% | -14% | 4.4% | – |
| EPS Diluted | -1.01 | -0.98 | -0.86 | -0.9 |
| Weighted Avg Shares Out | 56,126 | 55,927 | 55,744 | 53,944 |
| Weighted Avg Shares Out Dil | 56,126 | 55,927 | 55,744 | 53,944 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4,330 | $4,859 | $5,582 | $6,467 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,261 | $1,166 | $1,754 | -$4,921 |
| EBITDA | -$55,615 | -$58,290 | -$51,867 | -$61,038 |
| % Margin | -61,794.4% | -388,600% | -370,478.6% | -6,103,800% |